fogpharma.comHealthcare / BioTech & PharmaFounded: 2016Funding to Date: $868.26MM
FogPharma is a clinical-stage biotechnology research company striving to develop HeliconTM peptides, an innovative approach aimed at overcoming current medication limitations and creating drug solutions for all human disease drivers. The Helicons are intended to act similarly to antibodies and be allocated across tissue as they interact with small molecules within the cells, whereas most modern tailored medications have difficulty reaching these target areas. FogPharma was founded in 2016 and is headquartered in Cambridge, Massachusetts.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
03/01/2024 | Series E | $145MM | $xx.xx | $491.9MM | Nextech Invest, RA Capital Management, Rock Springs Capital, General Catalyst, Marshall Wace, Samsara Biocapital, Foresite Capital, Symbiosis, Catalio Capital Management, Sixty Degree Capital, Alex Gorsky | |
Price per Share
$xx.xx
Shares Outstanding
23,281,563
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Nextech Invest, RA Capital Management, Rock Springs Capital, General Catalyst, Marshall Wace, Samsara Biocapital, Foresite Capital, Symbiosis, Catalio Capital Management, Sixty Degree Capital, Alex Gorsky
|
||||||
11/21/2022 | Series D | $178MM | $xx.xx | $406.53MM | ARCH Venture Partners, Milky Way Investments, Fidelity, VenBio Partners, Deerfield Management, GV, Cormorant Asset Management, T. Rowe Price, Invus, Farallon Capital Management, HBM Healthcare Investments, Casdin Capital, PagsGroup | |
Price per Share
$xx.xx
Shares Outstanding
16,537,979
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.2x
Dividend Rate
800.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
ARCH Venture Partners, Milky Way Investments, Fidelity, VenBio Partners, Deerfield Management, GV, Cormorant Asset Management, T. Rowe Price, Invus, Farallon Capital Management, HBM Healthcare Investments, Casdin Capital, PagsGroup
|
||||||
03/01/2021 | Series C | $107MM | $xx.xx | $262.08MM | VenBio Partners, Cormorant Asset Management, Farallon Capital Management, Invus, GV, 6 Dimensions Capital, Deerfield Management, Blue Pool Capital | |
Price per Share
$xx.xx
Shares Outstanding
7,384,710
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.4x
Dividend Rate
800.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
VenBio Partners, Cormorant Asset Management, Farallon Capital Management, Invus, GV, 6 Dimensions Capital, Deerfield Management, Blue Pool Capital
|
||||||
05/16/2018 | Series B | $65.51MM | $xx.xx | $131.82MM | 6 Dimensions Capital, GV, Blue Pool Capital, Horizons Ventures, Nan Fung Group, Lerrink Partners, Deerfield Management, Boyu Capital, WuXi AppTec Corporate Ventures | |
Price per Share
$xx.xx
Shares Outstanding
4,658,112
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.3x
Dividend Rate
800.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
6 Dimensions Capital, GV, Blue Pool Capital, Horizons Ventures, Nan Fung Group, Lerrink Partners, Deerfield Management, Boyu Capital, WuXi AppTec Corporate Ventures
|
||||||
05/25/2016 | Series A | $11.11MM | $xx.xx | $37.05MM | Deerfield Management | |
Price per Share
$xx.xx
Shares Outstanding
1,434,062
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.1x
Dividend Rate
800.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Deerfield Management
|